Adding ruxolitinib (Jakafi) to standard graft-vs-host disease (GVHD) prophylaxis reduced incidence of acute and chronic GVHD while maintaining survival rates in patients with myelofibrosis undergoing ...
The combination of axatilimab-csfr (Niktimvo) with ruxolitinib (Jakafi) and/or belumosudil (Rezurock) yielded favorable responses in patients with severe chronic graft-vs-host disease (cGVHD), ...
Natural killer (NK) cells are the predominant innate lymphocyte subsets that mediate anti-tumor and anti-viral responses, and therefore possess promising clinical utilization. NK cells do not express ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback